Show simple item record

dc.contributor.authorSolomon, Ben
dc.contributor.authorCappuzzo, Fen
dc.contributor.authorFelip, Een
dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorCosta, Den
dc.contributor.authorKim, Den
dc.contributor.authorNakagawa, Ken
dc.contributor.authorWu, Yen
dc.contributor.authorMekhail, Ten
dc.contributor.authorPaolini, Jen
dc.contributor.authorTursi, Jen
dc.contributor.authorUsari, Ten
dc.contributor.authorWilner, Ken
dc.contributor.authorSelaru, Pen
dc.contributor.authorMok, Ten
dc.date.accessioned2016-04-18T08:48:11Zen
dc.date.available2016-04-18T08:48:11Zen
dc.date.issued2016-03-28en
dc.identifier.citationIntracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. 2016: J Clin Oncolen
dc.identifier.issn1527-7755en
dc.identifier.pmid27022118en
dc.identifier.doi10.1200/JCO.2015.63.5888en
dc.identifier.urihttp://hdl.handle.net/10541/605645en
dc.description.abstractIntracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titleIntracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014.en
dc.typeArticleen
dc.contributor.departmentBenjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractIntracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer.


This item appears in the following Collection(s)

Show simple item record